MAPK/ERK pathway: Difference between revisions
No edit summary |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
<StructureSection load='3i2t' size='350' side='right' scene='' caption='Glycosylated EGFR (PDB code [[3i2t]])'> | <StructureSection load='3i2t' size='350' side='right' scene='' caption='Glycosylated EGFR (PDB code [[3i2t]])'> | ||
MAPK/ERK pathway (also known as the Ras-Raf-MEK-ERK pathway) is a chain of proteins in the cell that communicates a signal from a receptor on the surface of the cell to the DNA in the nucleus of the cell. | MAPK/ERK pathway (also known as the Ras-Raf-MEK-ERK pathway) is a chain of proteins in the cell that communicates a signal from a receptor on the surface of the cell to the DNA in the nucleus of the cell. | ||
| Line 53: | Line 52: | ||
*The first drug licensed to act on this pathway is [[sorafenib]] — a Raf kinase inhibitor. | *The first drug licensed to act on this pathway is [[sorafenib]] — a Raf kinase inhibitor. | ||
*'''Dabrafenib''' ''e.g.'' [[4xv2]] - B-Raf Kinase V600E oncogenic mutant in complex with Dabrafenib. | *'''Dabrafenib''' ''e.g.'' [[4xv2]] - B-Raf Kinase V600E oncogenic mutant in complex with Dabrafenib. | ||
*B-Raf Kinase Inhibitor Zelboraf - Generic: '''Vemurafenib''' (Formerly: PLX-4032), see [[B-RAF with PLX4032]]. | *B-Raf Kinase Inhibitor Zelboraf - Generic: '''Vemurafenib''' (Formerly: PLX-4032), see [[B-RAF with PLX4032]]. | ||
===MEK inhibitor=== | |||
*'''Cobimetinib''' or XL518, approved by US FDA in Nov 2015 for use in combination with vemurafenib (Zelboraf(R)), for treatment of advanced melanoma with a BRAF V600E or V600K mutation (see above). [[4lmn]] - MEK1 kinase bound to MEK1 kinase bound to Cobimetinib (GDC0973). | |||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||